Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cytokinetics reported its second quarter 2026 results amid early-stage commercialization of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and positive clinical developments extending its cardiology pipeline.</li><li>The company highlighted encouraging commercial momentum, with U.S. net product revenues from MYQORZO reaching $23 million and European launch initiation, particularly in Germany, contributing an additional $2.3 million.</li><li>As of quarter-end, over 700 U.S. healthcare providers had prescribed MYQORZO, with more than 1,500 patients having received the drug, marking an approximate tripling from the first quarter.</li></ul>

Cytokinetics reported its second quarter 2026 results amid early-stage commercialization of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and positive clinical developments extending its cardiology pipeline.The company highlighted encouraging commercial momentum, with U.S. net product revenues from MYQORZO reaching $23 million and European launch initiation, particularly in Germany, contributing an additional $2.3 million.As of quarter-end, over 700 U.S. healthcare providers had prescribed MYQORZO, with more than 1,500 patients having received the drug, marking an approximate tripling from the first quarter.

Cytokinetics’ $23 Million MYQORZO Launch — Can Aficamten Become A Cardiology Powerhouse?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Cytokinetics is transitioning into a commercial-stage entity with the recent launch of its lead asset, MYQORZO (aficamten), a next-in-class cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM).</li>
  <li>The primary value driver is the commercial success of MYQORZO, which directly competes with Bristol Myers Squibb's Camzyos. Early uptake is strong, and MYQORZO may possess a more favorable clinical profile, potentially leading to a less restrictive REMS program and broader adoption.</li>
  <li>The company remains unprofitable with significant cash burn due to high R&amp;D and commercial launch expenses, creating a dependency on product revenue growth and potential future financing to support its broader pipeline development.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Cytokinetics is transitioning into a commercial-stage entity with the recent launch of its lead asset, MYQORZO (aficamten), a next-in-class cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM).
  The primary value driver is the commercial success of MYQORZO, which directly competes with Bristol Myers Squibb's Camzyos. Early uptake is strong, and MYQORZO may possess a more favorable clinical profile, potentially leading to a less restrictive REMS program and broader adoption.
  The company remains unprofitable with significant cash burn due to high R&amp;D and commercial launch expenses, creating a dependency on product revenue growth and potential future financing to support its broader pipeline development.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Cytokinetics Inc (CYTK US) - Aug 2026

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Index Rebalance

<ul>
<li>On Friday after the close, the S&amp;P DJI Index Committee announced changes to the S&amp;P 100, S&amp;P500, S&amp;P MidCap400, and S&amp;P SmallCap600. Changes happen at the close 15 March 2024.</li>
<li>
<a href="https://www.smartkarma.com/entities/super-micro-computer-inc" target="_blank" data-smartkarma-citation="entities:7921:1" rel="noopener">Super Micro Computer (SMCI US)</a> and <a href="https://www.smartkarma.com/entities/deckers-outdoor-corp" target="_blank" data-smartkarma-citation="entities:3028:1" rel="noopener">Deckers Outdoor (DECK US)</a> replace <a href="https://www.smartkarma.com/entities/zions-bancorporation" target="_blank" data-smartkarma-citation="entities:9490:1" rel="noopener">Zions Bancorporation (ZION US)</a> and <a href="https://www.smartkarma.com/entities/whirlpool-corp" target="_blank" data-smartkarma-citation="entities:1538:1" rel="noopener">Whirlpool Corp (WHR US)</a> in the S&amp;P500. 2 changes to 400, 6 to 600.</li>
<li>The immediate reaction was to send SMCI up 12.5%. That's shortsighted. It pays to count the pennies involved. There are a LOT of pennies.</li>
</ul>


On Friday after the close, the S&amp;P DJI Index Committee announced changes to the S&amp;P 100, S&amp;P500, S&amp;P MidCap400, and S&amp;P SmallCap600. Changes happen at the close 15 March 2024.

Super Micro Computer (SMCI US) and Deckers Outdoor (DECK US) replace Zions Bancorporation (ZION US) and Whirlpool Corp (WHR US) in the S&amp;P500. 2 changes to 400, 6 to 600.
The immediate reaction was to send SMCI up 12.5%. That's shortsighted. It pays to count the pennies involved. There are a LOT of pennies.


S&P 500/400/600 Index Rebal - It's Not The Trade You Think

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

<ul>
<li>
<a href="https://www.smartkarma.com/entities/super-micro-computer-inc" target="_blank" data-smartkarma-citation="entities:7921:1" rel="noopener">Super Micro Computer (SMCI US)</a> and <a href="https://www.smartkarma.com/entities/deckers-outdoor-corp" target="_blank" data-smartkarma-citation="entities:3028:1" rel="noopener">Deckers Outdoor (DECK US)</a> replace <a href="https://www.smartkarma.com/entities/whirlpool-corp" target="_blank" data-smartkarma-citation="entities:1538:1" rel="noopener">Whirlpool Corp (WHR US)</a> and <a href="https://www.smartkarma.com/entities/zions-bancorporation" target="_blank" data-smartkarma-citation="entities:9490:1" rel="noopener">Zions Bancorporation (ZION US)</a> in the <a href="https://www.smartkarma.com/entities/s-p-500-index" target="_blank" data-smartkarma-citation="entities:22886:1" rel="noopener">S&amp;P 500 INDEX</a> at the close on 15 March.</li>
<li>There are a bunch of inclusions, deletions and migrations across the <a href="https://www.smartkarma.com/entities/s-p-500-index" target="_blank" data-smartkarma-citation="entities:22886:1" rel="noopener">S&amp;P 500 INDEX (SPX INDEX)</a>, the S&amp;P Midcap 400 Index, and the S&amp;P SmallCap 600 Index.</li>
<li>The largest flows will be in the <a href="https://www.smartkarma.com/entities/s-p-500-index" target="_blank" data-smartkarma-citation="entities:22886:1" rel="noopener">S&amp;P 500 INDEX (SPX INDEX)</a> adds and the largest impact in the adds to the S&amp;P SmallCap 600 Index.</li>
</ul>



Super Micro Computer (SMCI US) and Deckers Outdoor (DECK US) replace Whirlpool Corp (WHR US) and Zions Bancorporation (ZION US) in the S&amp;P 500 INDEX at the close on 15 March.
There are a bunch of inclusions, deletions and migrations across the S&amp;P 500 INDEX (SPX INDEX), the S&amp;P Midcap 400 Index, and the S&amp;P SmallCap 600 Index.
The largest flows will be in the S&amp;P 500 INDEX (SPX INDEX) adds and the largest impact in the adds to the S&amp;P SmallCap 600 Index.


S&P500 Index Rebalance: SPCY Additions & Large Impact

<ul><li>Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in clinical trials focused on hypertrophic cardiomyopathy (HCM) and heart failure.</li><li>The launch of MYQORZO in the United States marked the company’s first approved therapy reaching patients, yielding net product revenues of $4.8 million during approximately nine weeks of commercial availability.</li><li>Early demand and healthcare provider (HCP) engagement exceeded internal expectations, supported by high prescriber awareness and favorable perceptions of MYQORZO’s clinical profile, including dosing flexibility, safety, and absence of drug-drug interaction requirements in the REMS (Risk Evaluation and Mitigation Strategy) program.</li></ul>

Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in clinical trials focused on hypertrophic cardiomyopathy (HCM) and heart failure.The launch of MYQORZO in the United States marked the company’s first approved therapy reaching patients, yielding net product revenues of $4.8 million during approximately nine weeks of commercial availability.Early demand and healthcare provider (HCP) engagement exceeded internal expectations, supported by high prescriber awareness and favorable perceptions of MYQORZO’s clinical profile, including dosing flexibility, safety, and absence of drug-drug interaction requirements in the REMS (Risk Evaluation and Mitigation Strategy) program.

Cytokinetics' MYQORZO Launch: Can Early HCM Demand Define The Next Phase?

United States

Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company.  The Company is focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cytokinetics Inc (CYTK US)

Cytokinetics’ $23 Million MYQORZO Launch — Can Aficamten Become A Cardiology Powerhouse?

Cytokinetics reported its second quarter 2026 results amid early-stage commercialization of MYQORZO (aficamten) for obstructive hypertrophic...

Baptista Research

Primer: Cytokinetics Inc (CYTK US) - Aug 2026

Cytokinetics is transitioning into a commercial-stage entity with the recent launch of its lead asset, MYQORZO (aficamten), a next-in-class...

αSK Primers

S&P 500/400/600 Index Rebal - It's Not The Trade You Think

The S&P DJI Index Committee announced the March index rebals. Everybody is looking at SMCI because it has run hard til now. That's missing the...

Travis Lundy

S&P500 Index Rebalance: SPCY Additions & Large Impact

There are bunch of adds, deletes and migrations for the SnP 500/400/600 indices in March. The largest inflows are on the SP500 adds but the largest...

Brian Freitas

Cytokinetics' MYQORZO Launch: Can Early HCM Demand Define The Next Phase?

Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Cytokinetics’ $23 Million MYQORZO Launch — Can Aficamten Become A Cardiology Powerhouse?

Cytokinetics reported its second quarter 2026 results amid early-stage commercialization of MYQORZO (aficamten) for obstructive hypertrophic...

Baptista Research

Primer: Cytokinetics Inc (CYTK US) - Aug 2026

Cytokinetics is transitioning into a commercial-stage entity with the recent launch of its lead asset, MYQORZO (aficamten), a next-in-class...

αSK Primers

S&P 500/400/600 Index Rebal - It's Not The Trade You Think

​The S&P DJI Index Committee announced the March index rebals. Everybody is looking at SMCI because it has run hard til now. That's missing the...

Travis Lundy

S&P500 Index Rebalance: SPCY Additions & Large Impact

There are bunch of adds, deletes and migrations for the SnP 500/400/600 indices in March. The largest inflows are on the SP500 adds but the largest...

Brian Freitas

Cytokinetics' MYQORZO Launch: Can Early HCM Demand Define The Next Phase?

Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in...

Baptista Research

The S&P DJI Index Committee announced the March index rebals. Everybody is looking at SMCI because it has run hard til now. That's missing the...